Hayley Virgil

A promising new treatment combination of frontline olaparib plus abiraterone/prednisone has emerged for advanced prostate cancer with specific genetic alterations.

Investigators report that response-adapted trials utilizing novel combination regimens appear to be safe and feasible in a population of patients with newly diagnosed diffuse large B-cell lymphoma.

Investigators report no new safety signals in patients with relapsed/refractory follicular lymphoma following treatment with tisagenlecleucel infusion.

The Dara-KRd regimen with double transplant induced deep response rates and a high minimal residual disease negativity rates among patients with high-risk, newly diagnosed multiple myeloma.

An analysis examined survival outcomes in several subgroups of patients with hematologic cancers compared with the overall population.

A sustained overall survival benefit has been reported from the phase 3 TROPiCS-02 study.

An update from the phase 3 NAPOLI 3 trial supports the use of NALIRIFOX for the first-line treatment of metastatic pancreatic ductal adenocarcinoma.

Among patients with newly diagnosed, advanced ovarian cancer, dose modifications to frontline niraparib maintenance therapy did not affect progression-free survival.

According to Vadim Gushchin, MD, treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of how it may impact a patient’s health-related quality of life.

Extended follow-up findings of the phase 3 CheckMate 274 study further support the use of nivolumab as a standard of care in high-risk muscle-invasive urothelial carcinoma following radical resection.

Compared with other tumor biomarkers, circulating tumor DNA may be ideal for early response assessment and have potential to enable use of adaptive clinical study designs in the future for patients with advanced colorectal cancer.

The use of 2 separate recommended phase 2 doses of Talquetamab was associated with high response rates in patients with heavily pre-treated relapsed/refractory multiple myeloma.

Treatment with various camizestrant monotherapy doses lead to survival benefit compared with fulvestrant in a post-menopausal patient population diagnosed with estrogen receptor–positive, HER2-negative advanced breast cancer.

Androgen deprivation therapy plus abiraterone acetate and prednisolone resulted in a clinically meaningful overall survival benefit, but this in combination with enzalutamide fell short in patients with metastatic hormone-sensitive prostate cancer.

Maintenance rucaparib (Rubraca) induced a progression-free survival (PFS) improvement in patients with newly diagnosed ovarian cancer compared with placebo, which was also seen across all prespecified subgroups.

Pembrolizumab and etoposide continues to demonstrate improvements in survival outcomes compared with placebo and etoposide in patients with previously untreated extensive stage-small cell lung cancer.

The combination of tremelimumab plus durvalumab and chemotherapy in the first-line elicited survival benefit in patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations.

Treatment with nivolumab and chemotherapy in patients with stage IIIA/B non–small cell lung cancer yielded significantly improved survival and responses, according to data from the phase 2 NADIM II study.

Atezolizumab may lead to improved overall survival when compared with the best supportive care in patients with resected non–small cell lung cancer.

Unique signaling pathways and significant differentially-expressed genes was found from 4 subgroups of patients with MET exon 14 skipping non–small cell lung cancer.

Treatment with concurrent sugemalimab demonstrated prolonged progression-free survival in patients with stage III unresectable non–small cell lung cancer.

Using neoadjuvant chemoimmunotherapy to treat patients with stage IIIA resectable non–small cell lung cancer based on differences between pathologic complete responders and non–pathologic complete responders is supported by the phase 2 NADIM trial.

In patients with relapsed/refractory large B-cell lymphoma, the chimeric antigen receptor T-cell agent, lisocabtagene maraleucel demonstrated durable responses.

According to a long-term analysis of the ZUMA-1 study, the overall survival rate yielded by axicabtagene ciloleucel may support 1- and 2-year event-free survival as a surrogate end point in relapsed/refractory large B-cell lymphoma.

In a first-in-human study, patients with advanced solid tumors experienced an increase in dose-dependent T-cell proliferation following treatment with MEDI5752.

In patients with non–small cell lung cancer who harbor a MET exon 14 skipping mutation, treatment with SCC244 appears efficacious.

In patients with early stage glottic larynx tumor-focused stereotactic radiotherapy showed benefit in a phase 2 study.

Patients with checkpoint inhibitor–naïve metastatic urothelial cancer had promising anti-tumor activity when treated with sacituzumab govitecan and pembrolizumab in the second-line setting.

Patients with advanced hepatocellular carcinoma achieved notable improvements in survival and responses following treatment with transarterial chemoembolization and lenvatinib.

Lisocabtagene maraleucel treatment in patients with relapsed or refractory B-cell lymphoma achieves long-lasting responses, study shows.